# Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

> **NCT01684163** · PHASE2 · COMPLETED · sponsor: **Naurex, Inc, an affiliate of Allergan plc** · enrollment: 369 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** GLYX-13 5 mg/kg
- **DRUG:** GLYX-13 10 mg/kg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01684163
- **Lead sponsor:** Naurex, Inc, an affiliate of Allergan plc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2014-04
- **Final completion:** 2014-06
- **Target enrollment:** 369 (ACTUAL)
- **Last updated:** 2016-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01684163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01684163, "Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01684163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*